Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Real-time Quote. Real-time Tradegate - 02/12 11:16:39 am
72.97 EUR   +2.13%
02/10 UCB : Enters into Research Agreement with Baylor College of Medicine
02/09 UCB : and Baylor College of Medicine launch strategic alliance in ne..
02/01 UCB : Executive Committee welcomes a new member
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UCB : Transparency notification of Vanguard Health Care Fund

04/11/2012 | 02:41pm US/Eastern

Participation on March 30, 2012 (according to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).

Brussels (Belgium), April 11, 2012 - 7.30 p.m. (CET) - regulated information - Vanguard Health Care Fund (having its registered offices c/o The Vanguard Group, 455 Devon Park Drive, Wayne, PA 19087 - USA) acquired 5,821,811 UCB shares with voting rights (on a total number of 183,365,052) on March 30, 2012, representing 3.17% of UCB's share capital, which means that Vanguard Health Care Fund crossed the threshold of notification of 3%.

UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608


For further information

Antje Witte, Investor Relations, UCB

T +32.2.559.9414, antje.witte@ucb.com

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

distributed by
React to this article
Latest news on UCB
02/10 UCB : Enters into Research Agreement with Baylor College of Medicine
02/09 UCB : and Baylor College of Medicine launch strategic alliance in neurodegenerat..
02/01 UCB : Executive Committee welcomes a new member
02/01 UCB : new epilepsy drug BRIVIACT® receives EU approval
02/01 UCB : Transparency notification
01/11 UCB : Transparency notification
2015 UCB : New Findings from UCB Pharma SA in the Area of Economic Dynamics Described..
2015 UCB : Transparency notification from BlackRock Inc
2015 LANNETT : Completes Major Acquisition Of Kremers Urban Pharmaceuticals For $1.23..
2015 UCB : Acquisition of own shares
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials